MSBU to promote Glatopa

Discussion in 'Novartis' started by Anonymous, Apr 16, 2015 at 9:59 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Sandoz and Novartis team up to leverage Gilenya commercial infastructure to promote generic copaxone. Novartis gets new leverage!
     

  2. Anonymous

    Anonymous Guest

    Same crappy leadership!
     
  3. Anonymous

    Anonymous Guest

    No need for a strenuous effort on a generic Copaxone or Extavia. Treat them as commodities and take market share with pricing and insurance formularies driving usage.
     
  4. Anonymous

    Anonymous Guest

    Anyone know how Novartis MS division calculates rep IC bonus? (Rx's, dollars, share??)I have an offer from them but forgot to ask the method by which they calculate bonus...
    Thanks!
     
  5. Anonymous

    Anonymous Guest

    There is no bonus and I would run from this job. You are making the biggest mistake of your life you have been warned.
     
  6. Anonymous

    Anonymous Guest

    Before you take the job find out about the manager. Do not work in Philly!!!
     
  7. Anonymous

    Anonymous Guest

    Thats great advice but doesn't answer my question...what determines the bonus methodology? (Rx's, share. dollars??)
     
  8. Anonymous

    Anonymous Guest

    SRF is 70% of your comp plan.
    30% market share! which you have little control over.....target bonus at 30k (very primary care like)

    If you have good relationships with your neuros just have them write a SRF for Gilenya every time they switch to an oral......doesn't matter if they go on. Not your problem. The entire field is doing this. From the managers (not all) up to the brand team, they have no clue how to run this business unit..... 4.5 years in and we have a 9% market share. That's a joke......
     
  9. Anonymous

    Anonymous Guest

    I heard that guy just lost a girl that had 15+ years at Novartis and another leave to do marketing in house. Add to that the Philly girl that left, this guy seems like a hoot to work for. At which point does his boss shake their head and ask WTF is this guy doing here....
     
  10. Anonymous

    Anonymous Guest

    The RD covers for him since he hired that loser. This guy should never manage people.
     
  11. Anonymous

    Anonymous Guest

    Let's clarify for those who do not work in the MSBU. Unless YOU have good relationships with your Neurologists you have little chance of marking decent bonus dollars. SRF is 70%. Which means if your Neurologists are not writing fake scripts for you that will never go through you will not hit the 70%. Potential new employees need to ask themselves if they know the doctors in their territory well. If you don't you will not make a good bonus.

    The bonus program encourages lying. It wastes resources because follow up is on fake scripts. If you are not familiar with the MS marketplace a 9% market share for the 1st oral is considered a complete failure. This business unit is a failure. They will state it is a billion dollar drug which is true but the missed potential is the key.
     
  12. Anonymous

    Anonymous Guest

    Thanks...but just to make sure of the reference here what exactly is SRF??
     
  13. Anonymous

    Anonymous Guest

    Service Request Form. Do not take this job you will be very sorry. Our new leader is terrible and you will be micromanaged to death. Don't expect to make over 15k in bonus.
     
  14. Anonymous

    Anonymous Guest

    Thank you for the heads up!
     
  15. Anonymous

    Anonymous Guest

    In MS the SRF is used as the prescription. If you go to the Dr for allergy meds the dr calls in a prescription to the pharmacy. With MS meds most drs fax in the SRF directly to the company (or the outside vendor who the company hires) and this acts as the patients prescription. Since Novartis makes a large part of the bonus related to SRFs, the only way to make money is to have the drs (or staff) fax in fake SRFs to the company. You get the bonus credit and the prescription never gets filled. The company wastes the resources of the vendor following up on the SRF. Novartis loses because they pay the bonus for a fake script and pay the vendor to waste their time. Also the nurse wastes time.

    The leadership of the MSBU cannot figure out how to effectively and efficiently run the business so they resort to making their employees "beat the system".

    Other MS companies have figured out the process, don't micromanage their employees, pay respectable bonuses, have minimum turnover, refuse to hire poor quality primary care managers, etc. Novartis never figured out the MS space and this is why a 9% market share is at 4 1/2 years after launch. We always question if the top leaders in Novartis are embarrassed or do the lower level managers spin the billion dollars in such a way that the upper leaders are impressed. A billion $ is not great when each patient brings in $60,000+ revenue per year. Now a billion $ is great if the prescription per patient brings in $500 per year, That's a lot of patients.
     
  16. Anonymous

    Anonymous Guest


    Great synopsis of the problems bravo. Now our new leader is a dumb blonde who has made things worse since she took over. We are the lowest paid MS salesforce and most are tanking it until they find a new job.
     
  17. Anonymous

    Anonymous Guest

    Thanks for the information. I've decided not to work for Novartis. There appears to be too many issues.
     
  18. Anonymous

    Anonymous Guest

    Anyone know how many total MSL's there are that support the Novartis MS division? Are they all traditional MSL's... or are some of them Community based MSL's? Thanks!
     
  19. Anonymous

    Anonymous Guest

    Stop asking on every thread moron get lost already.
     
  20. Anonymous

    Anonymous Guest

    I think it would be funny to see this BU leadership fuck up the number one selling ms drug.